Can engineered immune cells outsmart transplant-related cancer?

This early-phase trial tests a new type of immunotherapy for people who develop a rare blood cancer called post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. The treatment uses the patient's own immune cells (T-cells) that are engineered to resist the effects of tacrolimus, an immunosuppressant drug needed to prevent organ rejection. The goal is to see if these modified cells can safely fight the cancer while continuing to protect the transplanted organ. The trial compares the engineered cells to a control version to see which persists better in the body.